Startup profile · funding coverage
Alethio Therapeutics funding, valuation and investors
Oxford biotechnology company developing targeted treatments for myeloproliferative neoplasms.
Verified company research · funding, investors and latest developments
Keep track of Alethio Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$90M · November 5, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$90M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Oxford, United Kingdom
Investors in latest funding
Lead: Sofinnova Partners , RA Capital Management
Other: Oxford Science Enterprises
Overview
Alethio Therapeutics is an Oxford biotechnology spinout developing novel investigational treatments for myeloproliferative neoplasms, blood disorders involving abnormal marrow cell production. The lead ATX-011 is a G6B-targeting antibody; a second research program pursues mutant CALR. Its clinical development plans do not establish efficacy, safety or regulatory approval.
Why Alethio Therapeutics is interesting
Announced $90M Series A co-led by Sofinnova Partners and RA Capital on November 5, 2026; ATX-011 targets G6B in essential thrombocythaemia.
Product & use cases
Drug development, not an available product. The proposed pathway is antibody target validation for malignant hematopoietic disease, preclinical studies, regulatory permission, patient dosing trials and eventual pivotal efficacy trials if warranted. ATX-011 and CALR program are investigational.
- Investigational antibody-based treatment for essential thrombocythaemia and other myeloproliferative neoplasms.
Funding history (newest first)
Series A
2026-11-05 $90M- Sofinnova Partners (lead)
- RA Capital Management (lead)
- Oxford Science Enterprises (participant)
Competitive landscape
Edge: Novel G6B-targeting treatment hypothesis versus established JAK-pathway or symptom-directed care; actual clinical benefits await trials.
-
Incyte incumbent
Established JAK-inhibitor treatments in some myeloproliferative diseases; different mechanism and indications.
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.